Development and Validation of a Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma: a Retrospective Cohort Study.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- West China Hospital
- Enrollment
- 483
- Locations
- 1
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients. Intrahepatic cholangiocarcinoma is the second most common kind of primary liver cancer, accounting for approximately 10%-15%. There is a lack of agreement regarding the necessity of performing lymph node dissection (LND) in patients with ICC. Currently, the percentage of LND is below 50%, and the rate of sufficient LND (≥6) has plummeted to less than 20%. Consequently, a large proportion of patients are unable to acquire LN status, which hinders the following systematic treatment strategies after surgery:. Therefore, our objective is to construct a LN metastasis model utilizing machine learning techniques, including patients' clinical data and pathology information, with the goal of offering a reference for patients who have not undergone LND or have had inadequate LND.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •1.Patients who were confirmed with intrahepatic cholangiocarcinoma
- •curative-intent hepatectomy
- •Without concurrent extrahepatic disease
Exclusion Criteria
- •1.Patients lacking complete pathology information,
- •Patients who didn't get curative resection 3.Patients with concurrent extrahepatic disease or had missing follow-up data
Outcomes
Primary Outcomes
Overall survival
Time Frame: 2010.01-2019.01
Overall survival (OS) refers to the duration between the commencement of surgery and the patient's demise due to any reason.
Secondary Outcomes
- Disease free survival(2010.01-2019.01)
Investigators
Jiwei Huang
Dr.
Sichuan University